New Market Research Report: Type 2 Diabetes - Pipeline Review, H2 2015

Boston, MA -- (SBWire) -- 02/17/2016 --Global Markets Direct's, 'Type 2 Diabetes - Pipeline Review, H2 2015', provides an overview of the Type 2 Diabetes's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Get More Details on this Report and a Full Table of Contents at Type 2 Diabetes - Pipeline Review, H2 2015

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Report Scope

-The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes

-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in the therapeutics development for Type 2 Diabetes and enlists all their major and minor projects

-The report summarizes all the dormant and discontinued pipeline projects

-A review of the Type 2 Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-A detailed assessment of monotherapy and combination therapy pipeline projects

-Coverage of the Type 2 Diabetes pipeline on the basis of target, MoA, route of administration and molecule type

-Latest news and deals relating related to pipeline products

Reasons to Get this Report

-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Develop strategic initiatives by understanding the focus areas of leading companies

-Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes

-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

-Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned in this Report: 3SBio Inc., Addex Therapeutics Ltd, Adocia, Advinus Therapeutics Ltd., Aegis Therapeutics, LLC, AFFiRiS AG, Alchemia Limited, Alize Pharma SAS, AlphaMab Co., Ltd, Amarantus Bioscience Holdings, Inc., Ambrx, Inc., Amgen Inc., Anchor Therapeutics, Inc., AntriaBio, Inc., Aphios Corporation, Araim Pharmaceuticals Inc., Arisaph Pharmaceuticals, Inc., ArisGen SA, Array BioPharma Inc., Arrien Pharmaceuticals, LLC, Artery Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca Plc, AUS Bio Limited, Avaxia Biologics, Inc., Bayer AG, Beta-Cell NV, Betagenon AB, Biocon Limited, Biodel Inc., Biogenomics Limited, BioLingus AG, BioRestorative Therapies, Inc., BioTherapeutics Inc., BioTime, Inc., Boehringer Ingelheim GmbH, Boston Therapeutics, Inc., Braasch Biotech LLC, Bristol-Myers Squibb Company, C4X Discovery Limited, Caldan Therapeutics Limited, Cardax Pharmaceuticals, Inc., Cardiolynx AG, Carlina Technologies SAS, Carmot Therapeutics, Inc., Catabasis Pharmaceuticals, Inc., Celon Pharma Sp. z o.o., ChemoCentryx, Inc., Chipscreen Biosciences Ltd, Chong Kun Dang Pharmaceutical Corp., CJ HealthCare Corp., CohBar, Inc., Connexios Life Sciences Pvt. Ltd., CSL Limited, CureDM, Inc., CymaBay Therapeutics, Inc., Daewoong Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Dance Biopharm Inc., Debiopharm International S.A., Delpor, Inc., Diabetica Limited, Diabetology (Products) Ltd, DiaMedica Inc., Diasome Pharmaceuticals, Inc., DiscoveryBiomed, Inc., Dong-A Socio Group, Eisai Co., Ltd., Elcelyx Therapeutics, Inc., Eli Lilly and Company, enGene, Inc, Enzo Biochem, Inc., Epichem Pty Ltd, Esperion Therapeutics, Inc., Euroscreen S.A., Evotec AG, F. Hoffmann-La Roche Ltd., FibroStatin SL, Flamel Technologies S.A., Foresee Pharmaceuticals, LLC, Generex Biotechnology Corporation, Genfit SA, Genovate Biotechnology Co., LTD., GlaxoSmithKline Plc, Glide Pharmaceutical Technologies Limited, Glucox Biotech AB, Gubra ApS, GW Pharmaceuticals Plc, Hadasit Medical Research Services & Development Lt, Halozyme Therapeutics, Inc., HanAll Biopharma Co., Ltd., Handok Inc., Hanmi Pharmaceuticals, Co. Ltd., Heptares Therapeutics Limited, Hua Medicine Ltd., Hyundai Pharmaceutical Co., Ltd., Innopharmax Inc., Insusense Therapeutics ApS, Intarcia Therapeutics, Inc., Integral Molecular, Inc., IntelliCell BioSciences Inc., Intercept Pharmaceuticals, Inc., Intrexon Corporation, Ionis Pharmaceuticals, Inc., IPCA Laboratories Limited, Islet Sciences, Inc., iTherX, Inc., Japan Tobacco Inc., Jeil Pharmaceutical Co., Ltd., Jenrin Discovery, Inc., Jiangsu Hengrui Medicine Co., Ltd., Johnson & Johnson, Kadimastem Ltd., Kadmon Corporation, LLC, Kainos Medicine, Inc., Kareus Therapeutics, SA, Kissei Pharmaceutical Co., Ltd., Lexicon Pharmaceuticals, Inc., LG Life Science LTD., Ligand Pharmaceuticals, Inc., Lonestar Heart, Inc., Longevity Biotech, Inc, Magnus Life Science, Medesis Pharma S.A., Medestea Research & Production S.p.A., MedImmune, LLC, Mellitech SAS, Merck & Co., Inc., Mesoblast Limited, Metabolic Solutions Development Company, LLC, Metabolys S.A.S., MI.TO. Technology S.r.L., MicroBiome Therapeutics LLC, MidaSol Therapeutics LP, Mitsubishi Tanabe Pharma Corporation, Naia Limited, NatureWise Biotech & Medicals Corporation, NeoPharm Co., Ltd., Neurimmune Holding AG, Neurocrine Biosciences, Inc., NGM Biopharmaceuticals, Inc., Nimbus Therapeutics, LLC, NOD Pharmaceuticals, Inc., Nordic Bioscience A/S, Novartis AG, Novo Nordisk A/S, Noxxon Pharma AG, Omeros Corporation, OPKO Health, Inc., Oramed Pharmaceuticals, Inc., Orbis Biosciences, Inc., Orchid Chemicals & Pharmaceuticals Ltd, Orgenesis, Inc., Panacea Biotec Limited, Paras Biopharmaceuticals Finland Oy, Peptron, Inc., Pfizer Inc., PharmaIN Corporation, Pharnext SAS, PhaseBio Pharmaceuticals, Inc., Poxel SA, Progen Pharmaceuticals Limited, Prometheon Pharma, LLC, ProMetic Life Sciences Inc., ProteoTech, Inc., Prothena Corporation Plc, Purzer Pharmaceutical Co., Ltd., Quantum Pharmaceuticals, Reata Pharmaceuticals, Inc., Receptos, Inc., Red Glead Discovery AB, Regeneron Pharmaceuticals, Inc., reMYND NV, Rhizen Pharmaceuticals S.A., Rhythm Pharmaceuticals, Inc., Saniona AB, Sanofi, Sanwa Kagaku Kenkyusho Co., Ltd., SATT Conectus Alsace SAS, SBI Pharmaceuticals Co., Ltd., Seres Therapeutics, Inc., Serodus ASA, Serometrix, LLC, Sevion Therapeutics, Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Shanghai Pharmaceutical Co., Ltd., Shantani Proteome Analytics Pvt. Ltd., Shionogi & Co., Ltd., Sihuan Pharmaceutical Holdings Group Ltd., Sirona Biochem Corp, SJT Molecular Research, S.L., SK Chemicals Co., Ltd., Sprint Bioscience AB, Starpharma Holdings Limited, Stelic Institute & Co., Strongbridge Biopharma plc, Sumitomo Dainippon Pharma Co., Ltd., Summit Therapeutics Plc, Taisho Pharmaceutical Holdings Co., Ltd.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:
-Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015
-Type 2 Diabetes - Pipeline Review, H1 2015
-Dyslipidemia - Pipeline Review, H2 2015
-Herpes Simplex Infections - Pipeline Review, H2 2015
-Epilepsy - Pipeline Review, H2 2015